Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis

Journal of Rheumatology

Volumn 23, Issue 11, 1996, Pages 1849-1855

  Moreland, Larry W ^a,d   Margolies, Gary ^b   Heck Jr , Louis W ^a   Saway, Anthony ^b   Blosch, Consuelo ^c   Hanna, Roberta ^c   Koopman, William J ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Immunex Corporation ^*

^c AMGEN INC   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Rheumatoid arthritis; Treatment; Tumor necrosis factor receptor

Indexed keywords

C REACTIVE PROTEIN; HYBRID PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOXICITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0029858740     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Brennan FM, Feldmann M: Cytokines in autoimmunity. Curr Opin Immunol 1992;4:754-9.
2. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
3. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA: Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
4. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y: The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145-9.
5. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI: Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and then natural inhibitor, TIMP, in rheumatoid synovial fibroblasts. Matrix Suppl 1992;1:198-9.
6. Ahmadzadeb N, Shingu M, Nobunaga M: The effect of recombinant tumor necrosis factor-alpha on Superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990;8:387-91.
7. Moser RB, Schleiffenbaum B, Groscurth P, Fehr J: Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989;83:444-55.
8. Deleuran BW, Chu CQ, Field M, et at: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992;35:1170-8.
9. Westacott CI, Atkins RM, Dieppe PA, Elson CJ: Tumor necrosis factor-α receptor expression on chondrocytes isolated from human articular cartilage. J Rheumatol 1994;21:1710-5.
10. Engelmann H, Aderka, Rubinstein M, Rotman D, Wallach D: A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80.
11. Olsson I, Lantz M, Nilsson E, et al: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989;42:270-5.
12. Roux-Lombard P, Punzi L, Hasler F, et al: Soluble tumor necrosis receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
13. Barrera P, Boerbooms AM, Janssen EM et al: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993;36:1070-9.
14. Roux-Lombard P, Punzi L, Hasler F, et al: Soluble tumor necrosis receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
15. Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W: Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993;13:321-8.
16. Aderka D, Wysenbeek A, Engelmann H, et al: Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
17. Chikanza IC, Roux-Lomabard P, Dayer JM, Panayi GS: Tumor necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol 1993;92:19-22.
18. Zangerle R, Gallati H, Sarcletti M, et al: Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquired Immun Deficiency Syndromes 1994;7:79-85.
19. Kern P, Hernmer J, Gallati H, et al: Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis 1992;166:930-4.
20. Fumkawa S, Masubara T, Umezawa Y, Okumura K, Yabuta K: Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 1994;124:721-5.
21. Andus T, Gross V, Holstege A, et al: High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology 1992;16:749-55.
22. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frendsdorff A, Haran N: Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992;42:663-7.
23. Ward RA, Gordan L: Soluble tumor necrosis factor receptors are increased in hemodialysis patients. ASAIO J 1993;39:M782-6.
24. Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M: High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992;89:1690-3.
25. Elsasser-Beile U, Gallati H, Weber W, Wild ED, Schulte Monting J, von Kleist S: Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumour Biol 1994;15:17-24.
26. Froon AH, Bemelmans MH, Greve JW, van der Linden CG, Buurman WA: Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: Correlation with plasma creatinine values. Crit Care Med 1994;22:803-9.
27. Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;190:533-6.
28. Kraus T, Mehrabi A, Arnold J, et al: Evaluation of soluble tumor necrosis factor receptors with orthotopic liver transplantation. Transplant Proc 1992;24:2539-41.
29. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N: Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993;43:2679-82.
30. Austgulen R, Liabakk NB, Lien E, Espevik T: Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from newborns. Pediatric Res 1993;33:82-7.
31. Baumann P, Romero R, Berry S, et al: Evidence of participation of the soluble tumor necrosis factor receptor I in the host response to intrauterine infection in preterm labor. Am J Reprod Immunol 1993;30:184-93.
32. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM: Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1992;76:20-3.
33. Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
34. Nam MH, Reda D, Boujouko S, Agosti J, Suffredini AF: Recombinant human chimeric tumor necrosis factor (TNF) receptor (TNFR:Fc): Safety and pharmacokinetics in humans (abstr). Clin Res 1993:41.
35. Arnett FC, Edworth SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
36. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F: American College of Rheumatology, 1991, revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
37. Drevlow BE, Louis R, Haag MA, et al: Recombinant human interleukin-γ receptor, type I (rhuIL-1R1) in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum (In press).
38. Mullarkay MF, Leiferman KM, Peters MS, et al: Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994;152:2033-41.
39. Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
40. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effects of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
41. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor alpha. Eur J Immunol 1991;21:2575-9.
42. Keffer J, Probert L, Cazlaris H, et al: Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
43. Williams RO, Feldman M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
44. Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2767-6.
45. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;11:6602-7.
46. Elliot MJ, Maini RN, Feldmann M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum 1995;36:1681-90.
47. Elliott MJ, Maini RN, Feldman M, et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
48. Rankin ECC, Choy EHS, Kassimos D, et al: The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
49. Cope AP, Landei M, Chu NR, et al: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
50. Pennica D, Lam VT, Mize NK, et al: Biochemical properties of the 75-kDa tumor necrosis factor receptor: Characterization of ligand binding, internalization, and receptor phosphorylation. J Biological Chem 1992;267:21172-8.
51. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991;88:9292-6.
52. Gatanaga T, Hwang CD, Kohr W, et al: Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990;87:8781-4.
53. Ferrante A, Hauptmann B, Seckinger P, Dayer J-M: Inhibition of tumor necrosis factor alpha (TNF-α)-induced neutrophil respiratory burst by a TNF inhibitor. Immunology 1991;72:440-2.
54. Lantz M, Bjornberg F, Olsson I, Richter J: Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol 1994;152:1362-9.
55. Howard OMZ, Clouse KA, Smith C, Goodwin RG, Farrar WL: Soluble tumor necrosis factor receptor: Inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA 1993;90:2335-9.
56. Xenos ES, Farney AC, Widmer MB, et al: Effect of tumor necrosis factor alpha and of the soluble tumor necrosis factor receptor on insulin secretion of isolated islets of Langerhans. Transplant Proc 1992;24:2863-4.
57. Quinn TD, Miller RN, Wilson MA, Garrison RN, Anderson JA, Lenz LGE: Interleukin-2 induced lymphocyte infiltration of multiple organs is differentially suppressed by soluble tumor necrosis factor receptor. J Surg Res 1994;56:1717-22.